Nuvalent (NASDAQ:NUVL) Rating Lowered to “Hold” at Robert W. Baird

Nuvalent (NASDAQ:NUVL) was downgraded by stock analysts at Robert W. Baird from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

NUVL has been the topic of a number of other research reports. Cantor Fitzgerald lowered Nuvalent from an “overweight” rating to a “neutral” rating in a research note on Tuesday. TD Cowen lowered Nuvalent from a “buy” rating to a “hold” rating and set a $124.00 price target on the stock. in a research note on Tuesday. Barclays reiterated an “equal weight” rating and issued a $124.00 target price (down from $152.00) on shares of Nuvalent in a research report on Tuesday. Truist Financial set a $124.00 target price on Nuvalent in a research report on Tuesday. Finally, Guggenheim lowered Nuvalent from a “buy” rating to a “neutral” rating and dropped their target price for the company from $151.00 to $124.00 in a research report on Wednesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Nuvalent presently has a consensus rating of “Hold” and an average target price of $131.15.

Nuvalent Stock Performance

Shares of NUVL stock opened at $123.35 on Tuesday. Nuvalent has a fifty-two week low of $71.13 and a fifty-two week high of $123.62. The firm has a market capitalization of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15. The stock’s 50-day simple moving average is $103.44 and its 200-day simple moving average is $103.19.

Nuvalent (NASDAQ:NUVL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period last year, the firm posted ($1.18) earnings per share. As a group, equities analysts forecast that Nuvalent will post -5.74 earnings per share for the current year.

Insider Transactions at Nuvalent

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the sale, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. This represents a 4.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares in the company, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 126,953 shares of company stock worth $12,612,264 in the last ninety days. Corporate insiders own 5.02% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its position in shares of Nuvalent by 141.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Nuvalent during the 3rd quarter valued at approximately $38,000. NBC Securities Inc. purchased a new position in shares of Nuvalent during the 4th quarter valued at approximately $125,000. Finally, KBC Group NV lifted its position in shares of Nuvalent by 24.1% during the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after buying an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.